

DUPLICATE

Rec'd PCT/PTO 22 APR 2005

10532407

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number  
WO 2004/037226 A2

(51) International Patent Classification<sup>7</sup>: A61K 9/00 (74) Agent: WOLFF, BREGMAN AND GOLLER; P.O. Box 1352, 91013 Jerusalem (IL).

(21) International Application Number:  
PCT/IL2003/000862

(22) International Filing Date: 23 October 2003 (23.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/280,084 25 October 2002 (25.10.2002) US  
158,493 20 October 2003 (20.10.2003) IL

(71) Applicant (for all designated States except US): DEXCEL  
PHARMA TECHNOLOGIES LTD. [IL/IL]; P.O. Box  
23950, IL-91237 Jerusalem (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PENHASI, Adel  
[IL/IL]; 53/15 Rabinovich Street, IL-58671 Holon (IL).  
GOMBERG, Mila [IL/IL]; 608/8 Victor and Julius Street,  
IL-97482 Jerusalem (IL). AVRAMOFF, Avi [IL/IL]; 26  
Lea Street, IL-34405 Haifa (IL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,  
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 2004/037226 A2

(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING VENLAFAXINE

(57) Abstract: The invention provides a delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating that surrounds the core; said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter.

## FIELD OF THE INVENTION

The present invention relates to a formulation and method for the delayed burst release of venlafaxine.

## BACKGROUND OF THE INVENTION

Venlafaxine, 1-[(2-dimethylamino)-1-(4-methoxyphenyl) ethyl] cyclohexanol, is an important drug for the treatment of depression. Venlafaxine and the acid salts thereof are disclosed in U.S. Patent No. 4,535,186, which is hereby incorporated by reference as if fully set forth herein. Venlafaxine hydrochloride is presently administered to adults in compressed tablet form in doses ranging from 75 to 350 mg/day, in divided doses two or three times a day. Currently, in therapeutic dosing with venlafaxine hydrochloride tablets, rapid dissolution results in a rapid increase in blood plasma levels of the active compound shortly after administration followed by a decrease in blood plasma levels over several hours as the active compound is eliminated or metabolized, until subtherapeutic plasma levels are approached after about twelve hours following administration, thus requiring additional dosing with the drug. With the plural daily dosing regimen, the most common side effect is nausea, experienced by about forty five percent of patients under treatment with venlafaxine hydrochloride. Vomiting also occurs in about seventeen percent of the patients.

US Patent No. 6,274,171, issued on August 14, 2001, describes one attempted solution to the problem of frequent administration of venlafaxine. The disclosure teaches a formulation of spheroids, which is characterized by an outer film coating over a core which contains venlafaxine, and in which both are placed in a hard gelatine capsule. However, administration of this formulation results in blood concentration levels having a distinct peak 4-8 hours after administration.

Clearly, the ability to provide a more even plateau of blood concentration of venlafaxine, and therefore presumably to reduce the occurrence and/or severity of side effects, or even to eliminate such side effects altogether, as well as decreasing the frequency of administration of venlafaxine, would be desirable. In addition, the location of release of venlafaxine may also be problematic, as the above taught formulations clearly result in release occurring to a significant degree in the small intestine, and possibly also in the stomach. Since one of the most significant side effects of venlafaxine is nausea and/or vomiting, indicating gastric distress, clearly

release of this active ingredient should not occur in the stomach and/or small intestine.

In US Patents 6,403,120 and 6,419,958 there are described and claimed methods and compositions for providing therapeutic blood plasma concentration of venlafaxine over a twenty-four hour period with diminished incidence of nausea and emesis which comprises administering orally to a patient in need thereof, an extended release formulation as defined in said patents. More specifically one finds in both of said patents a specific description and definition of the term "extended release drug formulations" wherein both of said patents provide the same following description and definition:

"Extended release drug formulations are conventionally produced as compressed tablets by hydrogel tablet technology. To produce these sustained release tablet drug dosage forms, the active ingredient is conventionally compounded with cellulose ethers such as methyl cellulose, ethyl cellulose or hydroxypropylmethylcellulose with or without other excipients and the resulting mixture is pressed into tablets. When the tablets swell upon hydration from moisture in the digestive system, thereby limiting exposure of the active ingredient to moisture. As the cellulose ethers are gradually leached away by moisture, water more deeply penetrates the gel matrix and the active ingredient slowly dissolves and diffuses through the gel, making it available for absorption by the body. An example of such a sustained release dosage form of the analgesic/anti-inflammatory drug etodolac (Lodine ®) appears in US Pat. No. 4,966,768. US Pat. No. 4,389,393 discloses sustained release therapeutic compressed solid unit dose forms of an active ingredient plus a carrier base comprised of a high molecular weight hydroxypropylmethylcellulose, methyl cellulose, sodium carboxymethylcellulose and/or other cellulose ether."

Following the above description in said patents there is then presented a further description which states as follows:

"Where the production of tablets is not feasible, it is conventional in the drug industry to prepare encapsulated drug formulations which provide extended or sustained release properties. In this situation, the extended release capsule dosage forms may be formulated by mixing the drug with one or more binding agents to form a uniform mixture which is then moistened with water or a solvent such as

ethanol to form an extrudable plastic mass from which small diameter, typically of 1 mm, cylinders of drug/matrix are extruded, broken into appropriate lengths and transformed into spheroids using standard spheronization equipment. The spheroids, after drying, may then be film-coated to retard dissolution. The film-coated spheroids may then be placed in pharmaceutically acceptable capsules, such as starch or gelatin capsules, in the quantity needed to obtain the desired therapeutic effect. Spheroids releasing the drug at different rates may be combined in a capsule to obtain desired release rates and blood levels. US Pat. No. 4,138,475 discloses a sustained release pharmaceutical composition consisting of a hard gelatin capsule filled with film-coated spheroids comprised of propanolol in admixture with microcrystalline cellulose wherein the film coating is composed of ethyl cellulose, optionally, with hydroxypropylmethylcellulose and/or a plasticizer."

Said patents, having concluded and taught that the preferred solution for obtaining a flattened drug plasma concentration to time profile for extended release of venlafaxine is through use of such extended release drug formulations then specifically described at the top of column three of each of said patents that these formulations are achieved by providing a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine, hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

This is also the solution suggested and taught in US Patent 6,274,171 and in Patent Applications US 2002/0025339 and US 2001/0055612.

#### SUMMARY OF THE INVENTION

In contradistinction to the teachings of all of the above mentioned patents and applications that are based on extended release from microspheroids as a function of the structure and coating thereof, it has now been found that a different and better mechanism of long-term dispersion, e.g. for a period of at least 24 hours, of venlafaxine into the blood stream can be achieved by utilizing a formulation which provides for delayed burst release.

Thus, the present invention provides a delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating that surrounds the core;

said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and

said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter.

Preferably said water-insoluble hydrophobic carrier is relatively rigid.

In preferred embodiments of the present invention, there is provided a formulation, which releases substantially no venlafaxine *in vitro* for at least about two hours.

Thus, in preferred embodiments of the present invention, said *in vitro* delayed burst release occurs after at least about 2 hours.

In especially preferred embodiments of the present invention, there is provided a formulation wherein at least about 60% of the venlafaxine is released *in vitro* about one hour after said delayed burst release occurs.

In preferred embodiments of the present invention, said formulations are characterized in that substantially no venlafaxine is released *in vivo* until said delayed burst release occurs.

Thus in preferred formulations of the present invention, said *in vivo* release occurs after at least about 2 hours and in especially preferred embodiments of the present invention said *in vivo* release occurs after at least about 3 hours and in further formulations of the present invention, said *in vivo* release occurs after at least about 4 hours.

The invention is preferably further characterized in that it provides a method for treating a subject with venlafaxine, comprising administering to the subject a formulation having a therapeutically effective amount of venlafaxine or a pharmaceutically acceptable salt thereof, wherein said formulation provides a delayed burst release after at least three hours resulting in dispersion of the active ingredient mainly through the colon into the blood stream as a result of colon absorption over a period of at least 24 hours.

The delivery system of the present invention also advantageously uses the unique continuous absorption characterizing the colon, which results in more flat, consistent concentration levels of the drug in blood. Such an absorption, of course, can significantly contribute to reduce the fluctuations in blood drug concentration thus to prevent the side effects which may appear significantly upon using either

immediate or conventional controlled release formulations, thereby improving compliance.

The formulation preferably features a core, over which an outer coating is layered. The core is formed as a compressed tablet and comprises a burst controlling agent and a disintegrant.

The outer coating features a water insoluble, hydrophobic polymer, in which particles of a water insoluble but hydrophilic material are embedded. These particles preferably form channels upon contact with water or an aqueous medium, thereby enabling the active ingredient to be released upon the burst of the film coat.

In US Patent 5,840,332 there is described and claimed a gastrointestinal drug delivery system similar to that utilized in the present invention and the relevant teachings of said patent are incorporated herein by reference. It is to be noted however that the diseases contemplated and taught for treatment with such a formulation were selected from the group consisting of colitis, Crohn's disease, irritable bowel syndrome, gastritis, pancreatitis, hypertension, angina, arthritis, rheumatoid, arthritis, asthma, arrhythmia, local spasmolytic action, ulceration of the mucosa, diarrhea, constipation, polyps, carcinoma, cysts, infectious disorders, and parasitic disorders, and said patent does not teach nor suggest that said formulation would be effective for the administration of a drug such as venlafaxine for the treatment of depression.

Furthermore, as can be seen from comparative Example 11, table 4 and Figure 11 presented hereinafter, the formulation of the present invention provides a delayed burst release of venlafaxine resulting in a substantially even plasma concentration level of venlafaxine for a period extending over four hours, and a higher AUC (area under the blood concentration – time curve) when compared with the extended release formulations of venlafaxine presently available on the market and said patent neither teaches nor suggests the surprising characteristics of the venlafaxine formulations of the present invention as demonstrated in said example, table and figure.

Even more surprisingly, as can be seen from figures 12 and 13, and the description thereof presented hereinafter, the formulations of the present invention allow for the use of lower dosages since a formulation comprising about 60 mg according to the present invention provides bioequivalence of Efexor XR 75 mg and

provides similar bioavailability in the area under the concentration-time curve to Efexor XR 75 mg while formulations comprising about 120 mg according to the present invention provides bioequivalence of Efexor XR 150 mg and provides similar bioavailability in the area under the concentration-time curve to Efexor XR 150 mg.

Hereinafter, the term "venlafaxine" includes venlafaxine and pharmaceutically acceptable salts thereof, as disclosed for example in U.S. Patent No. 4,535,186, which was previously incorporated by reference.

The term "hydrophobic" when applied to a film means, besides its common definition, that the film is relatively non-permeable to water and to water-insoluble compounds. The term "hydrophilic" when applied to a film means, besides its common definition, that the film is relatively permeable to water and to water-soluble compounds.

The term "substantially sustained plateau" of blood concentration levels as used herein refers to a period of time during which the concentration of venlafaxine in the blood exhibits relatively low variability. The substantially sustained plateau preferably occurs for at least about four hours, but more preferably occurs for a longer period of time of at least about eight hours. By "relatively low variability", it is meant that on average, variability is preferably less than about 20% of the blood concentration, and more preferably is less than about 10% of the blood concentration. Similarly, the term "even blood concentration level" also refers to blood concentrations having relatively low variability as previously described.

The dosage levels of the active ingredient venlafaxine could easily be determined by one of ordinary skill in the art. In particular, effective dosages for venlafaxine are well known in the art.

According to the present invention, there is provided a delayed burst formulation as defined, wherein said formulation preferably provides a substantially sustained plateau of blood concentration level of venlafaxine in the subject, wherein said substantially sustained plateau is present for at least four hours.

Preferably the formulation comprises

(a) a core comprising the venlafaxine, wherein said core includes at least one burst controlling agent and a disintegrant, and wherein said core is formed as a compressed tablet; and

(b) an outer coating over said core, said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter, contained in the carrier, that forms channels in the outer coating, upon contact with water or an aqueous medium wherein said channels imbibe liquid and cause said at least one burst controlling agent to burst said coating, thereby enabling the delayed burst release of venlafaxine through these channels after at least three hours followed by dispersion of venlafaxine into the blood stream mainly through the colon over a period extending over at least twenty-four hours.

Also more preferably, the burst controlling agent comprises a water insoluble polymer for swelling upon contact with liquid, wherein the polymer does not form a hydrogel.

Most preferably, the water insoluble polymer is selected from the group consisting of cross-linked polysaccharide, water insoluble starch, microcrystalline cellulose, water insoluble cross-linked peptide, water insoluble cross-linked protein, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen modified cellulose, and cross-linked polyacrylic acid.

Preferably, said cross-linked polysaccharide is selected from the group consisting of insoluble metal salts or cross-linked derivatives of alginic, pectin, xantham gum, guar gum, tragacanth gum, and locust bean gum, carrageenan, metal salts thereof, and covalently cross-linked derivatives thereof.

Preferably, said modified cellulose is selected from the group consisting of cross-linked derivatives of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, carboxymethylcellulose, and metal salts of carboxymethylcellulose.

Also most preferably, the water insoluble polymer is calcium pectinate or microcrystalline cellulose.

Preferably, the core further comprises at least one of an absorption enhancer, a binder, a disintegrant, a hardness enhancing agent, and another excipient. More preferably, the binder is selected from the group consisting of starch, PVP (polyvinyl pyrrolidone), low molecular weight HPC (hydroxypropyl cellulose), low molecular weight HPMC (hydroxypropyl methylcellulose), low molecular weight carboxy methylcellulose, ethylcellulose, gelatin polyethylene oxide, acacia, dextrin,

magnesium aluminum silicate, and polymethacrylates. Also more preferably, the hardness enhancing agent is microcrystalline cellulose.

More preferably, the disintegrant is selected from the group consisting of crospovidone (cross-linked PVP) sodium carboxymethyl starch (sodium starch glycolate), cross-linked sodium carboxymethyl cellulose (Crocscarmellose), pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate and a combination thereof.

According to preferred embodiments of the present invention, the core further comprises a buffering agent. Preferably, the buffering agent is selected from the group consisting of an inorganic or organic alkaline salt compound.

Alternatively or additionally, the core further comprises a filler. Preferably, the filler is selected from the group consisting of microcrystalline cellulose, starch, lactitol, lactose, a suitable inorganic calcium salt, sucrose, or a combination thereof.

Also alternatively or additionally, the core further comprises a flow regulating agent. Preferably, the flow regulating agent includes at least one of colloidal silicon dioxide and aluminum silicate.

Preferably, the core further comprises a lubricant. More preferably, the lubricant is selected from the group consisting of stearate salts; stearic acid, talc, sodium stearyl fumarate, and compritol (glycerol behenate), or a combination thereof.

According to other preferred embodiments of the present invention, the water insoluble polymer being used in the film coating composition is relatively rigid. Preferably, the water insoluble polymer is selected from the group consisting of a dimethylaminoethylacrylate/ethylmethacrylate copolymer, the copolymer being based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups, wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is approximately 1:20, the polymer corresponding to USP/NF "Ammonio Methacrylate Copolymer Type A", an ethylmethacrylate/chlorotrimethylammoniummethyl methacrylate copolymer, the copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:40, the polymer corresponding to

USP/NF "Ammonio Methacrylate Copolymer Type B", a dimethylaminoethylmethacrylate/methylmethacrylate and butylmethacrylate copolymer, a copolymer based on neutral methacrylic acid esters and dimethylaminoethyl methacrylate esters wherein the polymer is cationic in the presence of acids, an ethylacrylate and methylacrylate/ethylmethacrylate and methyl methylacrylate copolymer, the copolymer being a neutral copolymer based on neutral methacrylic acid and acrylic acid esters, ethylcellulose, shellac, zein, and waxes.

According to still other preferred embodiments of the present invention, the water insoluble particulate matter in the film coating composition is selected from the group consisting of a water insoluble polysaccharide, a water insoluble cross-linked polysaccharide, a water insoluble polysaccharide metal salt including calcium pectinate, a water insoluble cross-linked protein, a water insoluble cross-linked peptide, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen, a water insoluble cross linked polyacrylic acid, a water insoluble cross-linked cellulose derivatives, water insoluble cross-linked polyvinyl pyrrolidone, microcrystalline cellulose, insoluble starch, microcrystalline starch and a combination thereof.

Preferably said particulate matter is microcrystalline cellulose.

Preferably, the outer coating further comprises a plasticizer. More preferably, the plasticizer includes at least one of dibutyl sebacate, polyethylene glycol and polypropylene glycol, dibutyl phthalate, diethyl phthalate, triethyl citrate, tributyl citrate, acetylated monoglyceride, acetyl tributyl citrate, triacetin, dimethyl phthalate, benzyl benzoate, butyl and/or glycol esters of fatty acids, refined mineral oils, oleic acid, castor oil, corn oil, camphor, glycerol and sorbitol or a combination thereof.

Also preferably, the outer coating further comprises a stiffening agent.

More preferably, the stiffening agent is cetyl alcohol.

Preferably, the outer coating further comprises at least one of a wetting agent, a suspending agent, and a dispersing agent, or a combination thereof. More preferably, the wetting agent is selected from the group consisting of poloxamer, polyoxyethylene ethers, polyoxyethylene sorbitan fatty acid esters (polysorbates), polyoxymethylene stearate, sodium lauryl sulfate, sorbitan fatty acid esters, benzalkonium chloride, polyethoxylated castor oil, and docusate sodium. Also more

preferably, the suspending agent is selected from the group consisting of alginic acid, bentonite, carbomer, carboxymethylcellulose, carboxymethylcellulose calcium, hydroxyethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, dextrin, gelatin, guar gum, xanthan gum, kaolin, magnesium aluminum silicate, maltitol, medium chain triglycerides, methylcellulose, polyoxyethylene sorbitan fatty acid esters (polysorbates), povidone (PVP), propylene glycol alginate, sodium alginate, sorbitan fatty acid esters, and tragacanth. Most preferably, the dispersing agent is selected from the group consisting of poloxamer, polyoxyethylene sorbitan fatty acid esters (polysorbates) and sorbitan fatty acid esters.

According to other preferred embodiments of the present invention, there is provided a method for providing a therapeutically effective amount of venlafaxine to a subject comprising:

administering orally to the subject a delayed burst release formulation comprising a core and an outer coating that surrounds the core;

said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, a burst controlling agent and a disintegrant; and

said coating comprising a water-insoluble hydrophobic carrier and a hydrophilic particulate matter.

The present invention also provides a method for a treating a subject with venlafaxine, comprising: administering to the subject a formulation having a therapeutically effective amount of venlafaxine or a pharmaceutically acceptable salt thereof. Preferably, the formulation comprises: (a) a core containing the venlafaxine, the core comprising a water insoluble, swellable polymer, and a disintegrant; and (b) a coating comprising a water insoluble, hydrophobic polymer and water-insoluble but hydrophilic particulate matter embedded in the polymer, for forming channels in the outer coating, upon contact with water or an aqueous medium wherein said channels imbibe liquid and cause at least one burst controlling agent to burst the coating, thereby releasing venlafaxine; wherein an amount of the disintegrant and the water insoluble swellable polymer is selected such that the core releases venlafaxine in a manner providing a substantially even blood concentration level of venlafaxine for a period extending over at least about four hours.

According to still another embodiment of the present invention, there is provided a method for providing enhanced bioavailability of venlafaxine in a subject, comprising: administering to the subject a formulation having a therapeutically effective amount of venlafaxine or a pharmaceutically acceptable salt thereof, wherein the formulation provides a substantially sustained plateau of blood concentration level of venlafaxine in the subject, the combination of preferential release in the colon and substantially sustained plateau of blood concentration level resulting in enhanced bioavailability of venlafaxine.

According to another embodiment of the present invention, there is provided a formulation for release of venlafaxine in the colon of a subject, comprising: (a) a core that comprises the venlafaxine, wherein the core includes at least one burst controlling agent and a disintegrant, and wherein the core is formed as a compressed tablet; and (b) an outer coating over the core, the outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter, contained in the carrier, for forming channels in the outer coating, upon contact with water or an aqueous medium, wherein said channels imbibe liquid and cause the at least one burst controlling agent to burst the coating, thereby releasing venlafaxine in a delayed burst release after at least three hours followed by dispersion of venlafaxine through the colon into the blood stream over a period extending over at least twenty-four hours.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

The invention is herein described, by way of example only, with reference to the accompanying drawings, wherein:

FIGS. 1-10 are graphic representations of in vitro release profiles of venlafaxine from the formulations as described in the following examples and according to the present invention;

FIG. 11 shows the in vivo release profile of venlafaxine in a bioavailability study.

FIGS. 12 and 13 are graphical representations of a bioequivalence study of two formulations of 60 mg according to the present invention, compared to a 75 mg formulation of the prior art, showing mean plasma venlafaxine concentration-time curves and mean plasma ODV concentration-time curves.

FIG. 14a is a tabular representation and FIG. 14b is a graphical representation of the burst time release and percentage release of 60 mg formulations of the present invention.

FIG. 15a is a tabular representation and FIG. 15b is a graphical representation of the burst time release and percentage release of 120 mg formulations of the present invention.

FIGS. 16a is a tabular representation and FIG. 16b is a graphical representation of the burst time release and percentage release of a 60 mg core burst formulation of the present invention, without its outer coating.

#### **DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The present invention is of a formulation for delayed burst release of an active ingredient at least 2 hours after ingestion and mainly in the colon in order to produce a more stable and less variable plateau of the concentration of the active ingredient in the body of the subject. Optionally and more preferably delayed burst release of the active ingredient from the formulation also increases the bioavailability of the active ingredient, although such an increase in bioavailability is not necessary in order to receive the benefit of the formulation according to the present invention. The formulation preferably releases the active ingredient, such as venlafaxine, in the colon.

The core is in the form of a compressed tablet and features a burst controlling agent. The burst controlling agent is preferably a water insoluble polymer that swells considerably but preferably does not form a hydrogel or any other type of strong gel. Examples of polymers include but are not limited to, an the group consisting of cross-linked polysaccharide, water insoluble starch, microcrystalline cellulose, water insoluble cross-linked peptide, water insoluble cross-linked protein, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen modified cellulose, and cross-linked polyacrylic acid.

More preferably, the water insoluble polymer at least includes calcium pectinate or microcrystalline cellulose or a combination thereof.

The core preferably also optionally contains one or more of an absorption enhancer, a binder, a disintegrant, another excipient or a combination thereof.

Preferred examples of a binder include but are not limited to starch, PVP (polyvinyl pyrrolidone), low molecular weight HPC (hydroxypropyl cellulose), low molecular weight HPMC (hydroxypropyl methylcellulose), low molecular weight carboxymethyl cellulose, ethylcellulose, gelatin, polyethylene oxide, acacia, dextrin, magnesium aluminum silicate, and polymethacrylates.

Preferred examples of a disintegrant include but are not limited to, Crospovidone (cross-linked PVP), sodium carboxymethyl starch (sodium starch glycolate), cross-linked sodium carboxymethyl cellulose (Croscarmellose), pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum) or a combination thereof.

Optionally and more preferably, the cores also contain a buffering agent such as magnesium stearate, sodium stearate, or any other inorganic or organic alkaline salt compound. Such a buffering agent may optionally at least assist in the maintenance of the pH of the environment of the core, and is more preferably used as needed for the stability of the active ingredient itself.

Other optional ingredients for the core include, but are not limited to, one or more of a filler, a flow regulating agent and a lubricant. Examples of suitable fillers include but are not limited to, microcrystalline cellulose (Avicel™), starch, lactitol, lactose, dibasic calcium phosphate or any other type of suitable inorganic calcium salt and sucrose, or a combination thereof. Examples of suitable lubricants include but are not limited to, stearate salts such as magnesium stearate, calcium stearate, and sodium stearate; stearic acid, talc, sodium stearyl fumarate, and compritol (glycerol behenate), or a combination thereof. Examples of suitable flow regulating agents include but are not limited to, colloidal silicon dioxide and aluminum silicate.

Next, the cores are coated with an outer coating, which includes at least one water insoluble hydrophobic carrier and at least one type of water insoluble but hydrophilic particles or particulate matter embedded in the water insoluble polymer. The coating is preferably designed so that when the formulation enters the gastrointestinal tract, the particles absorb liquid, thus forming channels that interconnect the core with the outer surface of the coating.

The water insoluble polymer is more preferably relatively rigid, and is optionally and more preferably selected from the group consisting of a

dimethylaminoethylacrylate/ethylmethacrylate copolymer, the copolymer being based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups, wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is approximately 1:20, said polymer corresponding to USP/NF "Ammonio Methacrylate Copolymer Type A", an ethylmethacrylate/chlorotrimethylammoniummethyl methacrylate copolymer, the copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:40, the polymer corresponding to USP/NF "Ammonio Methacrylate Copolymer Type B", a dimethylaminoethylmethacrylate/methylmethacrylate and butylmethacrylate copolymer, a copolymer based on neutral methacrylic acid esters and dimethylaminoethyl methacrylate esters wherein the polymer is cationic in the presence of acids, an ethylacrylate and methylacrylate/ethylmethacrylate and methyl methacrylate copolymer, the copolymer being a neutral copolymer based on neutral methacrylic acid and acrylic acid esters, ethylcellulose, shellac, zein, and waxes.

The water insoluble particulate matter is more preferably selected from the group consisting of a water insoluble cross-linked polysaccharide, a water insoluble cross-linked protein, a water insoluble cross-linked peptide, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen, water insoluble cross linked polyacrylic acid, water insoluble cross-linked cellulose derivatives, water insoluble cross-linked polyvinyl pyrrolidone, micro crystalline cellulose, insoluble starch, micro crystalline starch and a combination thereof.

The outer coating preferably includes at least one plasticizer. Examples of suitable plasticizers include but are not limited to, dibutyl phthalate, diethyl phthalate, dibutyl sebacate, triethyl citrate, tributyl citrate, acetylated monoglyceride, acetyl tributyl citrate, triacetin, dimethyl phthalate, benzyl benzoate, butyl and/or glycol esters of fatty acids, refined mineral oils, oleic acid, castor oil, corn oil, camphor, glycerol, polyethylene glycol, propylene glycol and sorbitol. The amount of plasticizer is optionally and more preferably in a range of from about 0 to about

50% weight per weight of the water insoluble polymer in the film coat. In addition or alternatively, a stiffening agent such as cetyl alcohol could optionally be used.

The outer coating may also optionally contain at least one of a wetting agent, suspending agent, surfactant, and dispersing agent, or a combination thereof, in addition to the plasticizer.

Examples of suitable wetting agents include, but are not limited to, poloxamer, polyoxyethylene ethers, polyoxyethylene sorbitan fatty acid esters (polysorbates), polyoxymethylene stearate, sodium lauryl sulfate, sorbitan fatty acid esters, benzalkonium chloride, polyethoxylated castor oil, docusate sodium.

Examples of suitable suspending agents include but are not limited to, alginic acid, bentonite, carbomer, carboxymethylcellulose, carboxymethylcellulose calcium, hydroxyethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, dextrin, gelatin, guar gum, xanthan gum, kaolin, magnesium aluminum silicate, maltitol, medium chain triglycerides, methylcellulose, polyoxyethylene sorbitan fatty acid esters (polysorbates), polyvinyl pyrrolidone (PVP), propylene glycol alginate, sodium alginate, sorbitan fatty acid esters, and tragacanth.

Examples of suitable surfactants include but are not limited to, anionic surfactants such as docusate sodium and sodium lauryl sulfate; cationic, such as cetrimide; nonionic, such as polyoxyethylene sorbitan fatty acid esters (polysorbates) and sorbitan fatty acid esters.

Examples of suitable dispersing agents include but are not limited to, poloxamer, polyoxyethylene sorbitan fatty acid esters (polysorbates) and sorbitan fatty acid esters.

The content of the wetting agent, surfactant, dispersing agent and suspending agent may optionally be in an amount of from about 0 to about 30% of the weight of the film coat of the formulation. A particularly preferred embodiment of the present invention features crospovidone (cross-linked PVP), calcium pectinate, microcrystalline cellulose, ethylcellulose, polyvinyl pyrrolidone (PVP), colloidal silicon dioxide, and magnesium stearate in the core. The coating for this embodiment preferably features ethyl cellulose, cetyl alcohol, microcrystalline cellulose or calcium pectinate (CaP). Optionally an enteric coating may be applied to these coated cores. Most preferably the enteric coating contains Eudragit L or

cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate succinate phthalate, hydroxypropyl methyl cellulose acetate succinate. This embodiment is particularly preferred for the administration of venlafaxine.

As described in greater detail below, other pharmaceutically acceptable excipients may also be used in the formulations of the present invention.

The combination of the selected materials for the core matrix and outer layer, and the relative concentrations thereof, as well as the thickness of the core matrix and outer layer, determine both the lag time, which is the time, post administration, when the release starts, as well as the rate of release of the drug.

As previously described, release of the drug is optionally possible through any type of mechanism, including but not limited to, disintegration, burst release, diffusion, permeation (release through pores or channels), or erosion, or a combination thereof. The type of mechanism may be destructive to the outer layer or non-destructive; the continuity and/or structure of the outer layer may be maintained, or altered and/or destroyed. Without wishing to be limited to a single mechanism, for the preferred embodiments of the present invention, both the outer layer and the core preferably permit the drug to be released through some type of destructive process, including but not limited to, burst release, erosion and disintegration of the core, or a combination thereof. However, a mixture of mechanisms is also possible.

Burst release is the preferred mechanism for release of the active ingredient. Without wishing to be limited by a single hypothesis, the preferred embodiment of the formulation according to the present invention preferably features a core, which contains a swellable material, covered by a coating, which includes a water insoluble hydrophobic carrier. The coating also includes water insoluble but hydrophilic particulate matter. When this particulate matter comes into contact with water or an aqueous medium, the particulate matter imbibes water and swells, thereby forming channels, which enable the water to enter the core. The swellable material in the core then swells and bursts the coating, after which the core more preferably disintegrates slowly or otherwise releases the active ingredient.

**EXAMPLES****Examples 1-10**

These examples are of illustrative implementations of the formulation according to the present invention with venlafaxine. It should be noted that all examples given herein use venlafaxine hydrochloride, referred to herein as "venlafaxine" for the purpose of brevity and without any intention of being limiting. The formulations were tested *in vitro* to determine the release profile, as described in greater detail below.

**Table 1: Different formulations of the core containing VLF, and CaP-containing TCDS coating**

Tablets content	560-8		560-11		560-15	
	Mg/tab	%	mg/tab	%	mg/tab	%
<b>Core:</b>						
Venlafaxine	85	26.8	85	26.6	85	26.6
Crospovidone	41.5	13.0	41.3	12.9	39	12.2
Ca Pectinate					47	14.7
Microcrystalline cellulose	166	52.2	169.3	52.9	128	40
Ethylcellulose						
Polyvinylpyrrolidone	15.9	5	16.0	5.0	13	4.0
Colloidal Silicon Dioxide	6.0	1.9	6.4	2.0	6	1.9
Magnesium Stearate	3.1	1.0	2.0	0.6	2	0.6
Total weight uncoated tablet	317.5	100	320	100	320	100
CaP Coating:	560-9		560-12		560-16	
CaP Ethylcellulose	47.6%					
Cetyl Alcohol	4.8%					
CaP	47.6%					

The *in vitro* release of venlafaxine from the above-referenced formulations was determined as follows. Six venlafaxine formulation tablets were inserted into individual dissolution cells, each of which contain 450 ml HCl (0.1 M). After two hours, the dissolution medium was changed by adding 450 ml of 100 mM potassium dihydrogen phosphate and adjusting the pH to pH=6.8. The sample was stirred with a VanKel paddle stirrer (Van Kel Inc., USA). Samples were automatically drawn from each dissolution cell to test tubes at various time points (every half-hour from 2.5 hours to 7 hours after the pH was adjusted to pH=6.8), and were analyzed by a UV (ultraviolet) light detection and analysis device. A VK 8000 autosampler was used to analyze the samples (Van Kel Inc., USA). The amount of venlafaxine hydrochloride was measured at 227 nm light, and the amount of drug released was calculated according to a standard set of calculations that are known in the art.

#### **Example 1 (560-9)**

The cores were manufactured by dry mixing. Venlafaxine HCl (34g) was mixed with colloidal silicon dioxide (2.4g). The obtained mixture was sieved by sieve 600 microns and blended with crospovidone (16.6g), microcrystalline cellulose (66.4g) and polyvinyl pyrrolidone (6g). Magnesium stearate (0.12g) was passed through mechanical sieve equipped with 600 micron screen into the mixture and blended.

#### **Tabletting**

The tablets' blend was compressed with WICK single punch tabletting press equipped with suitable punches for providing sufficient active material and hardness sufficient for subsequent coating.

#### **TCDS Coating**

The formed cores were then coated with a TCDS coating containing calcium pectinate. (Ingredients and concentrations given in the tables above.)

The coating process was prepared and performed as follows. A weighed quantity of ethyl cellulose 20 (0.30kg) was dissolved in ethanol (6.06 kg) to obtain clear solution, to which a weighed quantity of plasticizer (cetyl alcohol-0.03kg) was added and mixed with mechanical stirrer to complete dissolution. Microcrystalline Cellulose (0.3kg) was added and stirred to obtain a homogeneous suspension, which was stirred during the whole coating process.

The TCDS coating was performed in a perforated pan coater, with an applied spraying pressure of 2.5 Bar. The suspension was coated until the weight of the coating was about 40-50mg. The tablets were dried.

Figure 1 shows the results for the release of venlafaxine from formulation 560-9. As shown, release is delayed until 3 hours after being placed in the more basic medium, which is sufficient to demonstrate that venlafaxine would be preferentially released at the colon.

#### Example 2 (560-11)

Venlafaxine HCl(50 g) was mixed with disintegrator (cross-linked polyvinyl pyrrolidone-2.5g) and binder-polyvinyl pyrrolidone and the granulation solution (water purified) was added. The blend was mixed until sufficient consistency was achieved. The granulated blend was dried.

The dried granulation blend was milled to obtain the desired particle size distribution of the final granulation blend.

Next, the process of blending was performed for the second part of the core. Colloidal silicon dioxide (3.2 g) was mixed with an additional amount of crospovidone (18.5g) and sieved by a mechanical sieve equipped with a 600 micron screen into the previously obtained granulation blend. The obtained mixture was blended. Microcrystalline cellulose (84.7 g) was added into the mixture and the entirety was blended.

Magnesium stearate (1.0), which serves as lubricant, was passed through a mechanical sieve equipped with a 600 micron screen into the mixture and blended for 2 minutes. This last process formed the tabletting mixture.

The tabletting mixture was then compressed with a WICK single punch tabletting press equipped with suitable punches, as previously described.

The formed cores were then coated with TCDS coating that was prepared as follows. A weighed quantity of Ethylcellulose 20 (10g) was dissolved in ethanol (200g) to obtain a clear solution, to which a weighed quantity of plasticizer (cetyl alcohol-1.0g) was added and mixed with the mechanical stirrer to complete dissolution. Sieved calcium pectinate (10 g) was added and stirred to obtain a homogeneous suspension, which was stirred during the whole coating process.

The coating was performed in a perforated pan coater, with the temperature of the incoming air kept to 28-32°C and with an applied spraying pressure of 0.4 Bar. The tablets were dried in the oven at 35°C overnight.

Figure 2 shows the results for the release of venlafaxine from formulation 560-12. As shown, release is sufficiently delayed after being placed in the more basic medium to demonstrate that venlafaxine would be preferentially released at the colon.

### Example 3 (560-15)

Venlafaxine HCl (42.5g) was mixed with calcium pectinate (023.5g) and disintegrator (cross-linked polyvinyl pyrrolidone-3.5g), and the granulation solution (polyvinyl pyrrolidone 3g dissolved in 30g Ethanol) was added. The blend was mixed until sufficient consistency was achieved. The granulated blend was dried.

The dried granulation blend was milled to obtain the desired particle size distribution of the final granulation blend.

Next, the process of blending was performed for the second part of the core. Colloidal silicon dioxide (2.4 g) was mixed with granulate and sieved by a mechanical sieve equipped with a 600 micron screen. The obtained mixture was blended. Microcrystalline cellulose (51.2 g), cross-linked polyvinyl pyrrolidone (12.8g) and polyvinyl pyrrolidone-(2.8g) were added into the mixture and the entirety was blended.

Magnesium stearate(0.8g), which serves as lubricant, was passed through a mechanical sieve equipped with a 600 micron screen into the mixture and blended. This last process formed the tabletting mixture.

The tabletting mixture was then compressed with a WICK single punch tabletting press equipped with suitable punches, as previously described.

The TCDS coating was prepared and added as previously described in Examples 1 and 2, containing calcium pectinate.

Figure 3 shows the results for the release of venlafaxine from formulation 560-16. As shown, release is sufficiently delayed after being placed in the more basic medium to demonstrate that venlafaxine would be preferentially released at the colon.

**Table 2: Different formulations of the core containing VLF, and microcristalline cellulose-containing TCDS coating**

Tablets content	560-21		560-22		560-23		241201	
	mg/t	%	mg/tab	%	mg/tab	%	mg/tab	%
<b>Core:</b>								
<b>Venlafaxine</b>	85	26.6	85	26.6	85	26.6	84.85	26.52
<b>Crospovidone</b>	41.3	12.9	43.0	13.4	39	12.2	41.65	13.02
<b>Ca Pectinate</b>			47	14.7	47	14.7		
<b>Microcrystalline cellulose(Avicel PH 102)</b>	169.	52.9	134	41.9	128	40	170	53.12
<b>Ethylcellulose</b>	3			0.9				
<b>Polyvinylpyrrolidone</b>	16.0	5			13	4.0	15.1	4.72
<b>Colloidal Silicon Dioxide</b>	6.4	2.0	6.0	1.9	6	1.9	6.4	2.0
<b>Magnesium Stearate</b>	2.0	0.6	2.0	0.6	2	0.6	2.0	0.62
<b>Total weight uncoated tablet</b>	320	100	320	100	320	100	320	100
<b>Coating:</b>	560-24/A		560-24/B		560-24/C		241201	
<b>Ethylcellulose</b>	47.6%							
<b>Cetyl Alcohol</b>	4.8%							
<b>Microcrystalline cellulose(Avicel PH 101)</b>	47.6%							

**Example 4 (560-21)**

Venlafaxine HCl(50 g) was mixed with disintegrator (cross-linked polyvinylpyrrolidone-2.5g ) and binder-polyvinyl pyrrolidone (1g) and the granulation solution (water purified) was added. Colloidal silicon dioxide (0.6g) was added for

improvement porosity of granulate. The blend was mixed until sufficient consistency was achieved. The granulated blend was dried.

The remainder of the process was performed as previously described, except that the coating contained microcrystalline cellulose, to form formulation 560-24/A. As shown (Figure 4), release is sufficiently delayed after being placed in the more basic medium to demonstrate that venlafaxine would be preferentially released at the colon.

#### **Example 5 (560-22, 560-23)**

Venlafaxine HCl(30.3 g) was mixed with calcium pectinate (16.8g), and disintegrant (cross-linked polyvinylpyrrolidone-2.5g ) and the granulation solution (1.1 g Ethocel 7 in 15g Ethanol)) was added. The blend was mixed until sufficient consistency was achieved. The granulated blend was dried. The remainder of the process was performed as previously described.

The coating again contained microcrystalline cellulose, to form formulation 560-24/B. Again, as shown in Figure 5 release is sufficiently delayed after being placed in the more basic medium to demonstrate that venlafaxine would be preferentially released at the colon.

The formulation 560-23 was performed as for 560-22 but polyvinyl pyrrolidone was used as a binder instead of ethyl cellulose. The coating again contained microcrystalline cellulose, to form formulation 560-24/C. Figure 6 shows the release profile of the formulation 560-24C. As shown, the release is sufficiently delayed after being placed in the more basic medium to demonstrate that venlafaxine would be preferentially released at the colon.

#### **Example 6 (241201)**

##### **Granulation**

Venlafaxine HCl (1.697 kg) was granulated with binder (Povidone K-30-0.054kg) and disintegrant (cross-linked polyvinyl pyrrolidone-0.093kg), and water purified (0.275kg) was added.

The remainder of the process was performed as previously described. Figure 7 shows the results of the release profile for 241201. Figure 8 shows the results of the *in vitro* release for the formulation 241201E, which has a TCDS coating that contains microcrystalline cellulose, over which an enteric coat has been added. As shown, release is sufficiently delayed after being placed in the more

basic medium to demonstrate that venlafaxine would be preferentially released at the colon.

#### **Example 7 (180502)**

##### **Granulation**

Venlafaxine HCl (0.848kg) was granulated with calcium pectinate (0.700kg) and disintegrant (cross-linked polyvinyl pyrrolidone-0.070kg). Binder solution (Povidone K-30-0.0085kg) and purified water (0.350kg) was added.

The remainder of the process was performed as previously described. Figure 9 shows the results, for the formulation 180502, which has a TCDS coating that contains microcrystalline cellulose. This formulation shows a slightly delayed release, sufficient to show that release would preferentially occur in the colon.

#### **Example 9: (180502E)**

The process of example 8 was repeated with additional enterocoating after TCDS coating.

#### **Example 10: (560-74)**

Venlafaxine HCl (0.5kg) was granulated with binder (Povidone K-30 - 0.0162kg), and disintegrant (cross-linked polyvinyl pyrrolidone - 0.0274 kg) and purified water (0.081 kg).

The remainder of the process was performed as previously described. Figure 10 shows the in vitro release of venlafaxine of the formulation 560-74, which has a TCDS coating that contains microcrystalline cellulose. This formulation shows a delayed release, sufficient to show that release would preferentially occur in the colon.

#### **Example 11: Pilot Study of Bioavailability (Venlafaxine)**

A pilot study was undertaken to investigate the Pharmacokinetic profile of the test formulation 241201 for Venlafaxine DR 75 mg tablets, which were prepared as previously described above in a comparative study as compared with Effexor XL (extended release formulation).

The formulation according to the present invention was administered to fasting volunteers and blood samples were withdrawn pre-dose and at: 1, 2, 3, 4, 5, 6, 7, 7.5, 8, 8.5, 9, 10, 12, 15, 24, 36, 48 and 60 hours post-dose.

Plasma concentrations of venlafaxine were determined using an HPLC analytical method with UV detection.

**Table 3: Venlafaxine Formulations**

Tablets content	240402		180502		560-74		560-78	
	mg/ta	%	mg/tab	%	mg/tab	%	mg/tab	%
<b>Core:</b>								
Venlafaxine	84.85	26.5	84.85	26.5	135.8	22.6	67.9	22.6
Crospovidone	39	12.2	39	12.2	77.4	12.9	39	13.0
Ca Pectinate	70	21.9	70	21.9				
Sodium Lauril Sulphate							5	1.7
Microcrystalline cellulose(Avicel PH 102)	106.15	33.2	106.15	33.2	343.4	57.2	168	56.0
Polyvinylpyrrolidone	12	3.7	12	3.7	27.6	4.6	12.2	4.1
Colloidal Silicon Dioxide	6.1	1.9	6.1	1.9	12.0	2	6.0	2.0
Magnesium Stearate	1.9	0.6	1.9	0.6	3.8	0.6	1.9	0.6
Total weight uncoated tablet	320	100	320	100	600	100	300	100
TCDS Coating:	240402		180502		560-75/A		560-79	
Ethylcellulose	47.6%		47.6%					
Cetyl Alcohol	4.8%		4.8%					
Microcrystalline cellulose(Avicel PH 102)	47.6%		47.6%					
Enterocoating:	Eudragit L30 D55		76.8%					
Triethylcitrate	15.5%							
Talc	7.7%							

The presented values for all pharmacokinetic parameters are mean  $\pm$  SD and (range). These values were calculated for eight volunteers (n =7). The extent of absorption as reflected by the AUC values and the rate of absorption as reflected by the Cmax values as well as the rate of absorption as reflected by the Tmax values for volunteers using venlafaxine according to the present invention and Effexor XL are presented in Table 4 hereinafter

Figure 11 shows the blood concentration values for the venlafaxine DR formulation according to the present invention vs. Effexor ER after administration.

**Table 4: PHARMACOKINETIC PARAMETERS**

**Venlafaxine Test versus Efexor Reference**

	A'JC (ng x hour/ml)	Cmax (ng/ml)	Tmax (hours)
VENLAFAXINE DR 75 mg (DEXCEL) B.N. 241201	408.66 $\pm$ 300.80 (63.33 ; 957.43)	30.26 $\pm$ 16.90 (10.24 ; 57.02)	11.79 $\pm$ 2.51 (8.50 ; 15.00)
EFFEXOR XL 75 mg (WYETH) B.N. A990612A	38.39 $\pm$ 244.45 (21.73 ; 780.94)	2.24 $\pm$ 12.65 (5.63 ; 44.38)	6.00 $\pm$ 0.82 (5.00 ; 7.00)
RATIO* (90% ANOVA C.I.)	.30 (0.94 ; 1.81)	.38 (0.99 ; 1.92)	
DIFFERENCE** (RANGE)			5.79 $\pm$ 1.78 (3.50 ; 8.00)

The presented values for all pharmacokinetic parameters are mean  $\pm$  SD and (range).

\*The presented ratios are geometric means of the individual ratios between test and reference parameters. Parametric estimators and Parametric Confidence Intervals, based on the linear model with logarithmic transformation, are brought.

\*\*The presented differences are the mean results and the range of Tmax.

As stated hereinbefore and as can be seen from Figure 11 and Table 4, surprisingly the delayed burst release formulations of venlafaxine according to the present invention result in a more even plasma concentration over a longer period of time as well as a greater bio-availability, as reflected by the greater AUC, when compared with the extended release formulation of venlafaxine presently available on the market.

Referring now to figures 12 and 13, there is shown a bioequivalence study of two formulations of 60 mg according to the present invention as compared to two 75 mg reference formulations, which were Efexor XR 75 mg. These graphs show the result of single dose administration in ten healthy men volunteers. As will be noted from figure 12, the mean plasma venlafaxine concentration in the area under the concentration-time curve is substantially equivalent for the 60 mg formulation of the present invention and the 75 mg reference formulation. Additionally, the ODV plasma concentration over time is also substantially equivalent for the 60 mg formulation of the present invention and the 75 mg reference formulation.

Referring now to figures 14a and 14b, there are shown the dissolution *in vitro* of six 60 mg delayed burst release formulation tablets according to the present invention from which it can be seen that the tablets, according to the present invention, release substantially no venlafaxine for at least about 2 hours and that within about 1 hour after said delayed burst release occurs, over 70% of the venlafaxine was released from each of the tested tablets.

Referring now to figures 15a and 15b, there are shown the dissolution *in vitro* of six 120 mg delayed burst release formulation tablets according to the present invention from which it can be seen that the tablets, according to the present invention, release substantially no venlafaxine for at least about 2 hours and that within about 1 hour after said delayed burst release occurs, over 80% of the venlafaxine was released from each of the tested tablets.

Referring to figures 16a and 16b, there are shown the dissolution *in vitro* of three 60 mg burst release formulation tablets using only the uncoated core according to the present invention for comparative purposes, from which it can be seen that the burst core of the present invention when uncoated, releases more than 75% and an average of more than 85% of the venlafaxine within half a minute of burst release and that within about 1 minute after said burst release occurs, over

95% of the venlafaxine was released from each of the tested tablets. This, indicates that the core has a fast and an immediate release characteristic and no extended and sustained release nature is related to the uncoated core. This specific release profile of the core is resulted from both lack of any release controlling agent in the formulation of the core as well as the presence of the burst controlling agent and disintegrant as well.

These improved characteristics of the present formulations enable the administration of lower dosages of the active ingredient and the consequent reduction of undesirable side effects.

It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative examples and that the present invention may be embodied in other specific forms without departing from the essential attributes thereof, and it is therefore desired that the present embodiments and examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

**WHAT IS CLAIMED IS:**

1. A delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating that surrounds the core;  
said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and  
said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter.
2. The formulation of claim 1, wherein said burst controlling agent comprises a water insoluble polymer, wherein said polymer swells upon contact with fluid and does not form a hydrogel.
3. The formulation of claim 2, wherein said water insoluble polymer is selected from the group consisting of cross-linked polysaccharide, water insoluble starch, microcrystalline cellulose, water insoluble cross-linked peptide, water insoluble cross-linked protein, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen, modified cellulose, and cross-linked polyacrylic acid.
4. The formulation of claim 3 wherein said cross-linked polysaccharide is selected from the group consisting of insoluble metal salts or cross-linked derivatives of alginate, pectin, xantham gum, guar gum, tragacanth gum, and locust bean gum, carrageenan, metal salts thereof, and covalently cross-linked derivatives thereof.
5. The formulation of claim 3 wherein said modified cellulose is selected from the group consisting of cross-linked derivatives of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, carboxymethylcellulose, and metal salts of carboxymethylcellulose.
6. The formulation of claim 3, wherein said water insoluble polymer is calcium pectinate.
7. The formulation of claim 3, wherein said water insoluble polymer is microcrystalline cellulose.
8. The formulation of claim 1, wherein said disintegrant is selected from the group consisting of cross-linked polyvinylpyrrolidinone, sodium starch glycolate, cross-linked sodium carboxymethylcellulose, pregelatinized starch, microcrystalline

starch, water insoluble starch, calcium carboxymethylcellulose, magnesium aluminium silicate, and combinations thereof.

9. The formulation of claim 1, wherein said water-insoluble hydrophobic carrier is selected from the group consisting of dimethylaminoethylacrylate/ethylmethacrylate copolymer, ethyl methacrylate/chlorotrimethylammoniummethyl methacrylate copolymer, dimethylaminoethylmethacrylate/methylmethacrylate and butylmethacrylate copolymer, ethylacrylate and methylacrylate/ethylmethacrylate and methyl methylacrylate copolymer; ethylcellulose, shellac, zein, and waxes.

10. The formulation of claim 1 wherein said water-insoluble hydrophobic carrier is ethylcellulose.

11. The formulation of claim 1 wherein said water insoluble hydrophobic carrier is relatively rigid.

12. The formulation of claim 1, wherein said water insoluble particulate matter is selected from the group consisting of a water insoluble polysaccharide, a water insoluble cross-linked polysaccharide, a water insoluble polysaccharide metal salt including calcium pectinate, a water insoluble cross-linked protein, a water insoluble cross-linked peptide, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen, a water insoluble cross linked polyacrylic acid, a water insoluble cross-linked cellulose derivatives, water insoluble cross-linked polyvinyl pyrrolidone, microcrystalline cellulose, insoluble starch, microcrystalline starch and a combination thereof.

13. The formulation of claim 1, wherein said particulate matter is microcrystalline cellulose.

14. The formulation of claim 1, wherein said core further comprises at least one of an absorption enhancer, a binder, a hardness enhancing agent and an excipient.

15. The formulation of claim 14, wherein said binder is selected from the group consisting of starch, polyvinylpyrrolidone, low molecular weight hydroxypropylcellulose, low molecular weight hydroxypropylmethylcellulose, low molecular weight carboxymethylcellulose, ethylcellulose, gelatin polyethylene oxide, acacia, dextrin, magnesium aluminum silicate, and polymethacrylates.

16. The formulation of claim 14, wherein said hardness enhancing agent is microcrystalline cellulose.

17. The formulation of claim 1, wherein said core further comprises a buffering agent.
18. The formulation of claim 17, wherein said buffering agent is selected from the group consisting of an inorganic salt compound and an organic alkaline salt compound.
19. The formulation of claim 1, wherein said core further comprises a filler.
20. The formulation of claim 19, wherein said filler is selected from the group consisting of, starch, lactitol, lactose, an inorganic calcium salt, sucrose, and combinations thereof.
21. The formulation of claim 1, wherein said core further comprises a flow regulating agent.
22. The formulation of claim 21, wherein said flow regulating agent includes at least one of colloidal silicon dioxide and aluminum silicate.
23. The formulation of claim 1, wherein said core further comprises a lubricant.
24. The formulation of claim 23, wherein said lubricant is selected from the group consisting of stearate salts; stearic acid, talc, sodium stearyl fumarate, and glycerol behenate, or a combination thereof.
25. The formulation of claim 1, wherein said outer coating further comprises a plasticizer.
26. The formulation of claim 25, wherein said plasticizer is selected from the group consisting of dibutyl sebacate, polyethylene glycol and polypropylene glycol, dibutyl phthalate, diethyl phthalate, triethyl citrate, tributyl citrate, acetylated monoglyceride, acetyl tributyl citrate, triacetin, dimethyl phthalate, benzyl benzoate, butyl and/or glycol esters of fatty acids, refined mineral oils, oleic acid, castor oil, corn oil, camphor, glycerol and sorbitol or a combination thereof.
27. The formulation of claim 1, wherein said outer coating further comprises at least one of a wetting agent, a suspending agent, and a dispersing agent, or a combination thereof.
28. The formulation of claim 27, wherein said wetting agent is selected from the group consisting of poloxamer, polyoxyethylene ethers, polyoxyethylene sorbitan fatty acid esters, polyoxymethylene stearate, sodium lauryl sulfate, sorbitan fatty acid esters, benzalkonium chloride, polyethoxylated castor oil, and docusate sodium.

29. The formulation of claim 27, wherein said suspending agent is selected from the group consisting of alginic acid, bentonite, carbomer, carboxymethylcellulose, carboxymethylcellulose calcium, hydroxyethylcellulose, hydroxypropylcellulose, microcrystalline cellulose, colloidal silicon dioxide, dextrin, gelatin, guar gum, xanthan gum, kaolin, magnesium aluminum silicate, maltitol, medium chain triglycerides, methylcellulose, polyoxyethylene sorbitan fatty acid esters, polyvinylpyrrolidinone, propylene glycol alginate, sodium alginate, sorbitan fatty acid esters, and tragacanth.

30. The formulation of claim 27, wherein said dispersing agent is selected from the group consisting of poloxamer, polyoxyethylene sorbitan fatty acid esters and sorbitan fatty acid esters.

31. The formulation of claim 1, wherein said coating further comprises a stiffening agent.

32. The formulation of claim 31, wherein said stiffening agent is cetyl alcohol.

33. The formulation of claim 1, wherein the formulation releases substantially no venlafaxine *in vitro* for at least about two hours.

34. The formulation of claim 33, wherein said *in vitro* delayed burst release occurs after at least about 2 hours.

35. The formulation of claim 34, wherein at least about 60% of the venlafaxine is released *in vitro* about one hour after said delayed burst release occurs.

36. A delayed burst release formulation according to claim 1 wherein substantially no venlafaxine is released *in vivo* until said delayed burst release occurs.

37. The formulation of claim 36, wherein said *in vivo* release occurs after at least about 2 hours.

38. The formulation of claim 36, wherein said *in vivo* release occurs after at least about 3 hours.

39. The formulation of claim 36, wherein said *in vivo* release occurs after at least about 4 hours.

40. A method for providing a therapeutically effective amount of venlafaxine to a subject comprising:

administering orally to the subject a delayed burst release formulation comprising a core and an outer coating that surrounds the core;

said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, a burst controlling agent and a disintegrant; and

said coating comprising a water-insoluble hydrophobic carrier and a hydrophilic particulate matter.

41. The method of claim 40, wherein said core is formed as a compressed tablet.

42. A method for providing enhanced bioavailability of venlafaxine in a subject, comprising:

administering orally to the subject a delayed burst release formulation comprising a core and an outer coating that surrounds the core;

said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, a burst controlling agent and a disintegrant; and

said coating comprising a water-insoluble hydrophobic carrier and a hydrophilic particulate matter.

characterized in that the *in vivo* blood plasma concentration of venlafaxine is substantially zero for at least about two hours after oral administration.

43. The method of claim 42 wherein said formulation comprises about 30 to about 120 mg of venlafaxine, or a pharmaceutically acceptable salt thereof.

44. The method of claim 43, wherein said formulation comprises about 60 mg of venlafaxine, or a pharmaceutically acceptable salt thereof.

45. The method of claim 44, wherein said formulation provides bioequivalence to Efexor XR 75 mg.

46. The method of claim 44, wherein said formulation provides similar bioavailability in the area under the concentration-time curve to Efexor XR 75 mg.

47. The method of claim 43, wherein said formulation comprises about 120 mg of venlafaxine, or a pharmaceutically acceptable salt thereof.

48. The method of claim 47, wherein said formulation provides bioequivalence to Efexor XR 150 mg.

49. The method of claim 47, wherein said formulation provides similar bioavailability in the area under the concentration-time curve to Efexor XR 150 mg.

50. A method for providing a therapeutically effective amount of venlafaxine to a subject in need thereof, comprising:

administering orally to the subject a delayed burst release formulation comprising a core and an outer coating that surrounds the core;

said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, a burst controlling agent and a disintegrant; and

said coating comprising a water-insoluble hydrophobic carrier and a hydrophilic particulate matter.

characterized in that the *in vivo* blood plasma concentration of venlafaxine is substantially zero for at least about two hours after oral administration.

51. The method of claim 50, wherein said core is formed as a compressed tablet.
52. The method of claim 51, wherein the outer coating comprises a water insoluble hydrophobic carrier and a water insoluble particulate matter.
53. The method of claim 52, wherein said water insoluble hydrophobic carrier is selected from the group consisting of a ethylcellulose; dimethylaminoethylacrylate/ethylmethacrylate copolymer, ethyl methacrylate/chlorotrimethylammoniummethyl methacrylate copolymer; dimethylaminoethylmethacrylate/ methylmethacrylate and butylmethacrylate copolymer; ethylacrylate and methyl acrylate/ethyl meth acrylate and methyl methylacrylate copolymer; and acrylic acid esters, ethylcellulose, shellac, zein, and waxes.
54. The method of claim 52 wherein said water-insoluble hydrophobic carrier is ethylcellulose.
55. The method of claim 52 wherein said water insoluble hydrophobic carrier is relatively rigid.
56. The method of claim 52, wherein said water insoluble particulate matter is selected from the group consisting of a water insoluble cross-linked polysaccharide including calcium pectinate, a water insoluble cross-linked protein, a water insoluble cross-linked peptide, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen, a water insoluble cross linked polyacrylic acid, a water insoluble cross-linked cellulose derivatives, water insoluble cross-linked polyvinyl pyrrolidone, microcrystalline cellulose, insoluble starch, microcrystalline starch, and combinations thereof.
57. The method of claim 52, wherein the core further comprises a burst controlling agent and a disintegrant.

58. The method of claim 55, wherein said burst controlling agent comprises a water insoluble polymer, wherein said water insoluble polymer swells upon contact with liquid and does not form a hydrogel.

59. The method of claim 58, wherein said water insoluble polymer is selected from the group consisting of cross-linked polysaccharide, water insoluble starch, microcrystalline cellulose, water insoluble cross-linked peptide, water insoluble cross-linked protein, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen, modified cellulose, and cross-linked polyacrylic acid.

60. The method of claim 59 wherein said cross-linked polysaccharide is selected from the group consisting of insoluble metal salts or cross-linked derivatives of alginate, pectin, xantham gum, guar gum, tragacanth gum, and locust bean gum, carrageenan, metal salts thereof, and covalently cross-linked derivatives thereof.

61. The method of claim 59 wherein said modified cellulose is selected from the group consisting of cross-linked derivatives of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, carboxymethylcellulose, and metal salts of carboxymethylcellulose.

62. The method of claim 58, wherein said water insoluble polymer is calcium pectinate.

63. The method of claim 58, wherein the water insoluble polymer is microcrystalline cellulose.

64. The method of claim 52, wherein said water-insoluble hydrophobic carrier is relatively rigid.

65. The method of claim 57, wherein said disintegrant is selected from the group consisting of polyvinylpyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethylcellulose, pregelatinized starch, microcrystalline starch, water insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate, and combinations thereof.

66. The method of claim 50, wherein the delayed burst release provides a blood concentration variability of venlafaxine in said subject which varies less than about 20% over a period of at least 4 hours.

67. The method of claim 66, wherein said blood concentration variability is less than about 10%.

68. The method of claim 50, wherein said core further comprises at least one of an absorption enhancer, a binder, a hardness enhancing agent, and an excipient.

69. The method of claim 68, wherein said binder is selected from the group consisting of starch, polyvinyl pyrrolidone, low molecular weight hydroxypropyl cellulose, low molecular weight hydroxypropyl methylcellulose, low molecular weight of carboxymethylcellulose, ethylcellulose, gelatin polyethylene oxide, acacia, dextrin, magnesium aluminum silicate, and polymethacrylates.

70. The method of claim 50, wherein said core further comprises a buffering agent.

71. The method of claim 70, wherein said buffering agent is selected from the group consisting of an inorganic salt compound and an organic alkaline salt compound.

72. The method of claim 50, wherein said core further comprises a filler.

73. The method of claim 72, wherein said filler is selected from the group consisting of starch, lactitol, lactose, inorganic calcium salt, and sucrose, or a combination thereof.

74. The method of claim 50, wherein said core further comprises a flow regulating agent.

75. The method of claim 74, wherein said flow regulating agent is selected from the group consisting of colloidal silicon dioxide and aluminum silicate, or a combination thereof.

76. The method of claim 50, wherein said core further comprises a lubricant.

77. The method of claim 76, wherein said lubricant is selected from the group consisting of stearate salts, stearic acid, talc, sodium stearyl fumarate, glycerol behenate, and combinations thereof.

78. The method of claim 50, wherein said outer coating further comprises a plasticizer.

79. The method of claim 78, wherein said plasticizer is selected from the group consisting of dibutyl sebacate, polyethylene glycol and polypropylene glycol, dibutyl phthalate, diethyl phthalate, triethyl citrate, tributyl citrate, acetylated monoglyceride, acetyl tributyl citrate, triacetin, dimethyl phthalate, benzyl benzoate, butyl and/or glycol esters of fatty acids, refined mineral oils, oleic acid, castor oil, corn oil, camphor, glycerol sorbitol, and combinations thereof.

80. The method of claim 50, wherein said outer coating further comprises a stiffening agent.

81. The method of claim 80, wherein said stiffening agent is cetyl alcohol.
82. The method of claim 50, wherein said outer coating further comprises at least one of a wetting agent, a suspending agent, a dispersing agent, or a combination thereof.
83. The method of claim 82, wherein said wetting agent is selected from the group consisting of poloxamer, polyoxyethylene ethers, polyoxyethylene sorbitan fatty acid esters, polyoxymethylene stearate, sodium lauryl sulfate, sorbitan fatty acid esters, benzalkonium chloride, polyethoxylated castor oil, and docusate sodium.
84. The method of claim 82, wherein said suspending agent is selected from the group consisting of alginic acid, bentonite, carbomer, carboxymethylcellulose, carboxymethylcellulose calcium, hydroxyethylcellulose, hydroxypropylcellulose, colloidal silicon dioxide, dextrin, gelatin, guar gum, xanthan gum, kaolin, magnesium aluminum silicate, maltitol, medium chain triglycerides, methylcellulose, polyoxyethylene sorbitan fatty acid esters, polyvinylpyrrolidone, propylene glycol alginate, sodium alginate, sorbitan fatty acid esters, and tragacanth.
85. The method of claim 82, wherein said dispersing agent is selected from the group consisting of poloxamer, polyoxyethylene sorbitan fatty acid esters and sorbitan fatty acid esters.
86. The method of claim 50, wherein said formulation provides a delayed burst release after at least three hours resulting in dispersion mainly through the colon of the active ingredient into the blood stream as a result of colon absorption over a period of at least 24 hours.
87. The method of claim 86, wherein said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter, contained in the carrier, that forms channels in said outer coating upon contact with the colon medium, wherein said channels imbibe liquid and cause said at least one burst controlling agent to burst said coating, thereby enabling the delayed burst release of venlafaxine after at least three hours followed by dispersion of venlafaxine into the blood stream mainly through the colon over a period extending over at least twenty-four hours.
88. A formulation for release of venlafaxine mainly in the colon of a subject, comprising:

(a) a core that comprises an effective amount of venlafaxine, wherein said core contains at least one burst controlling agent and a disintegrant, and wherein said core is formed as a compressed tablet; and

(b) an outer coating over said core, said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter, contained in the carrier, that forms channels in said outer coating material upon contact with the colon medium, wherein said channels imbibe liquid and cause said at least one burst controlling agent to burst said coating, thereby providing delayed burst release of venlafaxine after at least three hours followed by dispersion of venlafaxine into the blood stream mainly through the colon over a period extending over at least twenty-four hours.

## AMENDED CLAIMS

[received by the International Bureau on 26 July 2004 (26.07.04);  
original claims 89-93 have been added.

(a) a core that comprises an effective amount of venlafaxine, wherein said core contains at least one burst controlling agent and a disintegrant, and wherein said core is formed as a compressed tablet; and

(b) an outer coating over said core, said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter, contained in the carrier, that forms channels in said outer coating material upon contact with the colon medium, wherein said channels imbibe liquid and cause said at least one burst controlling agent to burst said coating, thereby providing delayed burst release of venlafaxine after at least three hours followed by dispersion of venlafaxine into the blood stream mainly through the colon over a period extending over at least twenty-four hours.

89. A method for providing a therapeutic blood plasma concentration of venlafaxine over a twenty-four hour period with diminished fluctuations in blood drug concentration said method comprising administering orally to a patient in need thereof, a delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating that surrounds the core; said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter.

90. A method according to claim 89 wherein said formulation provides a delayed burst release after at least three hours resulting in dispersion of the active ingredient mainly through the colon into the blood stream as a result of colon absorption over a period of at least twenty-four hours.

91. A method for providing a therapeutic blood plasma concentration of venlafaxine over a twenty-four hour period with diminished side effects said method comprising administering orally to a patient in need thereof, a delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating


that surrounds the core; said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter.

92. A method according to claim 91 wherein said formulation provides a delayed burst release after at least three hours resulting in dispersion of the active ingredient mainly through the colon into the blood stream as a result of colon absorption over a period of at least twenty-four hours.

93. A method for obtaining improved patient compliance in venlafaxine usage comprising administering orally to a patient in need thereof, a delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating that surrounds the core; said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter.

1/19

FIGURE 1




10/532407

CT/IL2003/000862

WO 2004/037226

2/19

FIGURE 2




10/532407

WO 2004/037226

CT/IL2003/000862

3/19

FIGURE 3




10/532407

WO 2004/037226

CT/IL2003/000862

4/19

FIGURE 4




10/532407

WO 2004/037226

CT/IL2003/000862

5/19

FIGURE 5




10/532407

WO 2004/037226

CT/IL2003/000862

6/19

FIGURE 6




10/532407

WO 2004/037226

CT/IL2003/000862


7/19

FIGURE 7



8/19

FIGURE 8




10/532407

WO 2004/037226

CT/IL2003/000862

9/19

FIGURE 9



10/532407

WO 2004/037226

CT/IL2003/000862

10/19

FIGURE 10




Fig. 11




FIG 12




FIG 13




FIG 14a

## % Release

Time, h	#1	#2	#3	#4	#5	#6
0	0	0	0	0	0	0
1.25	0	0	0	0	0	0
1.5	0	0	0	0	0	0
1.75	0	0	0	0	0	0
2	0	0	0	0	0	0
2.25	71	70.9	68.1	47	82.3	57.4
2.5	75.6	99.4	74.4	65.9	87.3	68.2
2.75	78.6	105	78.5	69.9	89.7	73.7
3	81.3	106.9	81.6	73.2	91.5	77.8
3.5	85.5	107.3	86	78.2	93.8	85
4	89.2	107.5	89	82.5	95.5	90.8
4.5	92	107.5	91.2	85.8	96.4	95.3
5	94.4	107.7	93.1	88.6	97.1	98.6
5.5	96.5	107.7	94.7	90.8	97.8	101
6	98.2	107.8	95.9	92.7	98.2	103
7	100.3	107.9	97.6	95.7	98.8	105.6
8	101.7	108.3	98.5	97.7	99.3	107


10/532407

WO 2004/037226

CT/IL2003/000862

15/19

FIG. 14b



10/532407

WO 2004/037226

16/19

CT/IL2003/000862

FIG 15a

## % Release

Time, h	#1	#2	#3	#4	#5	#6
0	0	0	0	0	0	0
1.25	0	0	0	0	0	0
1.5	0	0	0	0	0	0
1.75	0	0	0	0	0	0
2	0	0	0	0	0	0
2.25	0	0	10.1	0	0	0
2.5	29.8	81.9	81.2	56.2	76.8	64.3
2.75	85.8	87.2	86.1	72.9	82.3	73.9
3	91.2	97.2	88	80.5	86.4	77.8
3.5	94.7	101.0	91	88.9	91.5	82.8
4	96.3	101.8	93.7	93.6	94.6	87.2
4.5	97.6	103.4	95.6	96.6	96.4	90.8
5	98.8	104.2	97	98.4	97.7	93.7
5.5	99.3	104.6	98.2	99.8	98.2	95.6
6	100	105	99.1	100.6	98.5	96.8
7	100.6	105.9	100.1	102	98.9	98.5
8	101	106.2	101	102.6	99	100.4

10/532407


WO 2004/037226

CT/LL2003/000862

17/19

FIG. 15b

Dissolution of Venlafaxine 120 mg Delayed Release Tablets  
B.N.060503 (DEXCEL). App. 2, 50 rpm, 900 ml, 1 hour in 0.1N HCl,  
then 7 hours in buffer pH 6.8.



10/532407

WO 2004/037226

18/19

CT/IL2003/000862

FIG 16a

Time, min	#1(%)	#2(%)	#3(%)	Average(%)
0		0	0	0.0
0.5	94.2	90	78.6	87.6
1	97.4	96.1	95.5	96.3
2	101.2	98.7	99.5	99.3
3	102.7	99.5	101	101.1
5	104.1	101.3	101.4	102.3

FIG. 16b

